APOE and Alzheimer disease: The analyses reported in this paper suggest that trials of therapies which target hippocampal neurogenesis in preclinical or prodromal AD may benefit from the targeted selection of participants with reduced CSF Aβ42 and/or those with two ApoE ∈4 alleles.